Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx

• Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A…

Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo

• Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chr…

Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK

Mortality in patients with SpA Abstract #0569 #ACR22 @RheumNow ✏️systematic review/meta-analysis of 19 studies ✋No increased mortality in patients with PsA compared to gen. pop. 🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients

How do we know what PMR is all about? Imaging has helped enormously, and every step of the way, imaging has got better and better. Specific findings which reveal the culpable pathology. @drceowen #ACR22 @RheumNow https://t.co/4OOOk0F3jW

NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting. https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF

• https://bit.ly/3WZ6P6D

#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO 83% SRI4 response in TEL vs 38% PBO (p<0.001) As early as w4, sustained to w52 Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI @RheumNow #ACRBest https://t.co/UpEwEaonDO

Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz

• The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum …

Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU

• Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with …

L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts 157 pts, f/u 154 days 24 breakthrough COVID ifns (15%) 2 pts required hospitalization, rest had mild-mod symptoms No SAEs (CVD) @RheumNow

#ACR22 Best in PsA and SpA - new Rxs, unraveling responses to Rx by sex/gender. X-ray inhibition w SpA drugs is a reality. Nice peeps working in these areas @RheumNow @ACRheum https://t.co/8VfdyyHPZi

• https://twitter.com/uptotate/status/1592127498992631810

Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt

Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE

• Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of…

Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K

• Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis t…

Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6

• A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled T…